Please login to the form below

Not currently logged in
Email:
Password:

RDX5791

This page shows the latest RDX5791 news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    RDX5791 is an orally administered inhibitor of NHE3, a protein essential in the absorption of sodium in the intestines. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....